Flow Cytometry Core

流式细胞术核心

• 批准号: 8375338
• 负责人: DAVID R. PARKS
• 金额: $ 10.34万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8375338
• 关键词: Blood; Blood specimen; Cell Separation; Cells; Data; Ensure; Flow Cytometry; Hematopoietic; Hematopoietic stem cells; Human; Institutes; Laboratories; Mus; Normal Cell; Operative Surgical Procedures; Pathologist; Population; Process; Reporting; Research Personnel; Sampling; Schedule; Solid; Solid Neoplasm; Sorting - Cell Movement; Specimen; Speed; Stem cells; Tissues; Tumor Stem Cells; Uncertainty; Universities; Work; base; cancer cell; cancer stem cell; leukemic stem cell; neoplastic cell; operation; prospective; therapeutic target; tumor

Flow cytometry was first used to isolate a stem cell when the laboratory of Dr. Irving Weissman reported the prospective identification of mouse hematopoietic stem cells in 1986. In 2008, flow cytometry still sets the standard for cell enrichment. Thus, a state of the art flow cytometry core is critical for the isolation of solid tumor and leukemia stem cells for the 3 projects of this proposal. When working with human specimens obtained from the pathologist, one cannot predict with certainty when a specimen will arrive. This is predominantly because of the inherent uncertainty of surgical scheduling and issues that arise during an operation. The successful isolation of cancer stem cells is dependent upon the speed in which a tumor or blood sample is processed and sorted. Thus, one must be able to access a flow cytometer quickly for studies involving human tumor cells. This ensures that each tumor sample is analyzed in a timely and efficient manner, and data from each precious sample is not compromised by delays in processing because of lack of access to a flow cytometer. This is one of many reasons why the Stanford University Stem Cell Institute has established a flow cytometry core for the use of investigators in the Institute. Although commercial flow cytometers are quite sophisticated, they need to be modified for optimal isolation of cells from different tissues. In addition, each of the flow cytometers in this core has been modified so that both hematopoeitic and solid tissue stem cells can be isolated using optimal conditions. This is made possible in part by the core leader, David Parks. Based on Institute user's needs, the flow cytometers receive customized factory components. In addition, factory settings have been modified by the core PI to optimize sorting efficiency of both blood and solid tissue stem cells.

当欧文·韦斯曼博士的实验室报告说，流式细胞仪首先用于分离干细胞 前瞻性鉴定小鼠造血干细胞于1986年。2008年，流式细胞仪仍然设定 细胞富集的标准。因此，最先进的流式细胞仪核心对于固体的隔离至关重要 该提案的3个项目的肿瘤和白血病干细胞。与人类标本一起工作时 从病理学家那里获得，无法确定标本何时到达。这是 主要是由于手术调度的固有不确定性以及在 手术。癌症干细胞的成功分离取决于肿瘤或 处理并分类血液样本。因此，必须能够快速访问流式细胞仪 涉及人类肿瘤细胞的研究。这样可以确保及时分析每个肿瘤样本 有效的方式和每个珍贵样本的数据不会因处理的延迟而受到损害，因为 缺乏进入流式细胞仪的访问。这是斯坦福大学干细胞的众多原因之一 研究所已经建立了一个流式细胞仪核心，用于在研究所使用研究人员。虽然 商业流式细胞仪非常复杂，需要修改它们以最佳分离细胞 来自不同的组织。另外，该核心中的每个流式细胞仪都已修改，以便 可以使用最佳条件来分离血肿和固体组织干细胞。这是可能的 由核心领导人戴维·帕克斯（David Parks）的一部分。根据研究所用户的需求，流式细胞仪接收 定制的工厂组件。此外，核心PI已修改了工厂设置以优化 分类血液和固体组织干细胞的效率。